NDC 70518-0695

ODEFSEY

Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Alafenamide

ODEFSEY is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Remedyrepack Inc.. The primary component is Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Alafenamide Fumarate.

Product ID70518-0695_575e629d-c8d8-1a63-e053-2991aa0ae40b
NDC70518-0695
Product TypeHuman Prescription Drug
Proprietary NameODEFSEY
Generic NameEmtricitabine, Rilpivirine Hydrochloride, And Tenofovir Alafenamide
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2017-08-17
Marketing CategoryNDA / NDA
Application NumberNDA208351
Labeler NameREMEDYREPACK INC.
Substance NameEMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
Active Ingredient Strength200 mg/1; mg/1; mg/1
Pharm ClassesNucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Non-Nucleoside Analog [EXT],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
NDC Exclude FlagE
Listing Certified Through2018-12-31

Packaging

NDC 70518-0695-0

30 TABLET in 1 BLISTER PACK (70518-0695-0)
Marketing Start Date2017-08-17
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 70518-0695-0 [70518069500]

ODEFSEY TABLET
Marketing CategoryNDA
Application NumberNDA208351
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-08-17
Marketing End Date2020-05-01

Drug Details

Active Ingredients

IngredientStrength
EMTRICITABINE200 mg/1

OpenFDA Data

SPL SET ID:0f7e4fbb-b6a8-4be9-81a4-c92e288a33d9
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1741733
  • 1741739
  • Pharmacological Class

    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Non-Nucleoside Analog [EXT]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

    NDC Crossover Matching brand name "ODEFSEY" or generic name "Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Alafenamide"

    NDCBrand NameGeneric Name
    50090-2340ODEFSEYemtricitabine, rilpivirine, and tenofovir alafenamide
    61958-2101ODEFSEYemtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide
    70518-0695ODEFSEYemtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide

    Trademark Results [ODEFSEY]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    ODEFSEY
    ODEFSEY
    86553716 4879988 Live/Registered
    Gilead Sciences Ireland UC
    2015-03-04

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.